The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials

Objective: While gynaecological cancer patients who participate in Phase I clinical trials are not routinely considered for elective surgery because of a short life expectancy, this should not be overlooked in carefully selected responding patients. Methods/Results: We describe two cases of patients with different gynaecological cancers, who received treatment within separate phase I trials, and who then proceeded to surgical resection of their cancers, resulting in complete remission. Conclusion: Surgery, when feasible, should be taken into consideration as a potential management option, even when patients are receiving treatment within a phase I trial.

Phase I trial; Gynaecological cancers; Surgery

[1] Eisenhauer E.A., O’Dwyer P.J., Christian M., Humphrey J.S.: “Phase I clinical trial design in cancer drug development”. J. Clin. Oncol., 2000, 18, 684.

[2] Vlastos G., Smith D.L., Singletary S.E., Mirza N.Q., Tuttle T.M., Popat R.J. et al.: “Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases”. Ann. Surg. Oncol., 2004, 11, 869.

[3] Shah S.A., Haddad R., Al-Sukhni W., Kim R.D., Greig P.D., Grant D.R. et al.: “Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma”. J. Am. Coll. Surg., 2006, 202, 468.

[4] Han L., Kristelett R., van Hagen T., Yap T., Olmos D., Carden C. et al.: “Characterizing the experience of gynecologic oncology patients in phase I studies”. Gynecol. Oncol., 2010, 115, S59.

[5] Pekmezci S., Saribeyoglu K., Aytac E., Arvas M., Demirkiran F., Ozguroglu M.: “Surgery for isolated liver metastasis of ovarian cancer”. Asian J. Surg., 2010, 33, 83.

[6] Ushijima K.: “Treatment for recurrent ovarian cancer-at first relapse”. J. Oncol., 2010, 497, 429.

[7] Ferenschild F.T., Vermaas M., Verhoef C., Ansink A.C., Kirkels W.J., Eggermont A.M., Wilt J.H.: “Total pelvic exenteration for primary and recurrent malignancies”. World J. Surg., 2009, 33, 1502.

[8] Yamamoto K., Yoshikawa H., Shiromizu K., Saito T., Kuzuya K., Tsunematsu R., Kamura T.: “Pulmonary metastasectomy for uterine cervical cancer: a multivariate analysis”. Ann. Thorac. Surg., 2004, 77, 1179.

[9] Tangjitgamol S., Levenback C.F., Beller U., Kavanagh J.J.: “Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review”. Int. J. Gynecol. Cancer, 2004, 14, 399.

[10] Merideth M.A., Cliby W.A., Keeny G.L., Lesnick T.G., Nagorney D.M., Podratz K.C.: “Hepatic resection for metachronous metastases from ovarian carcinoma”. Gynecol. Oncol., 2003, 89, 16.

[11] Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M. et al.: “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial”. Lancet, 2010, 376, 245.

[12] Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roevink M., Gourley C. et al.: “Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval”. J. Clin. Oncol., 2010, 28, 2512.

[13] Shih J., Yang C., Su W., Hsia T.C., Tsai C.M., Chen Y. et al.: “A Phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)”. J. Clin. Oncol., 2009, 27, 15s.

[14] Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D.: “Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study”. J. Clin. Oncol., 2009, 27, 1069.

[15] Homesley H.D., Meltzer N.P., Nieves L., Vaccarello L., Lowendoski G.S., Elbendary A.A.: “A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer”. Int. J. Clin. Oncol., 2008, 13, 62.